METHODS FOR THE PREVENTION OR TREATMENT OF ANTHRAX INFECTION

1 . A method for treating a Bacillus anthracis (anthrax) infection in a subject, comprising administering to the subject a pharmaceutical composition consisting of a therapeutically effective amount of telavancin or a pharmaceutically acceptable salt thereof and at least one pharmaceutical excipient.

2 . The method of claim 1 , wherein the telavancin or pharmaceutically acceptable salt thereof is telavancin hydrochloride.

3 . The method of claim 1 , wherein the at least one pharmaceutical excipient is selected from the group consisting of: 2-hydroxypropyl-β-cyclodextrin, mannitol, sodium hydroxide, hydrochloric acid, 5% Dextrose Injection, Sterile Water for Injection, Sodium Chloride Injection, and combinations thereof.

4 . The method of claim 1 , wherein pharmaceutical composition is administered to the subject within 15 minutes of diagnosis of Bacillus anthracis infection or exposure to Bacillus anthracis.

5 . The method of claim 1 , wherein pharmaceutical composition is administered to the subject within 48 hours of diagnosis of Bacillus anthracis infection or exposure to Bacillus anthracis.

6 . The method of claim 1 , wherein the pharmaceutical composition is administered intravenously to the subject.

7 . The method of claim 1 , wherein the therapeutically effective amount is from 7.5 mg/kg to 15 mg/kg body weight of the subject.

8 . The method of claim 1 , wherein the pharmaceutical composition is administered once daily to the subject.

9 . The method of claim 1 , wherein the subject is a mammal.

10 . The method of claim 1 , wherein the Bacillus anthracis is a vegetative form of B. anthracis , a B. anthracis spore or a mixture of both.

11 . The method of claim 1 , wherein the Bacillus anthracis infection is selected from the group consisting of cutaneous anthrax, gastrointestinal anthrax, inhalational anthrax, or injection anthrax.

12 . The method of claim 1 , wherein the telavancin or a pharmaceutically acceptable salt thereof is the only antibiotic administered to the subject for treating the Bacillus anthracis infection.

13 . A method for preventing a Bacillus anthracis (anthrax) infection in a subject at risk of exposure to Bacillus anthracis , comprising administering to the subject a pharmaceutical composition consisting of a therapeutically effective amount of telavancin or a pharmaceutically acceptable salt thereof and at least one pharmaceutical excipient.

14 . The method of claim 13 , wherein the pharmaceutical composition is administered less than 24 hours prior to the risk of exposure.

15 . The method of claim 13 , wherein the pharmaceutical composition is administered less than 15 days prior to the risk of exposure.

16 . A method for treating or preventing a Bacillus anthracis (anthrax) infection in a mammal, comprising intravenously administering to the mammal a pharmaceutical composition comprising a therapeutically effective amount of telavancin hydrocholoride and at least one pharmaceutical excipient selected from the group consisting of: 2-hydroxypropyl-β-cyclodextrin, mannitol, sodium hydroxide, hydrochloric acid, 5% Dextrose Injection, Sterile Water for Injection, 0.9% Sodium Chloride Injection, and combinations thereof.

17 . The method of claim 16 , wherein the Bacillus anthracis infection is selected from the group consisting of cutaneous anthrax, gastrointestinal anthrax, inhalational anthrax, or injection anthrax.

18 . The method of claim 16 , wherein the Bacillus anthracis is a vegetative form of B. anthracis , a B. anthracis spore or a mixture of both.

19 . The method of claim 16 , wherein the telavancin hydrochloride is the only antibiotic administered to the mammal for the treatment or prevention of the Bacillus anthracis infection.

20 . The method of claim 16 , wherein the pharmaceutical composition is administered once daily to the mammal.